Stomach cancer is a growth of abnormal tissues that form a tumor in the part of your abdomen. Symptoms of stomach cancer often include persistent abdominal pain, extreme heartburn, extreme vomiting, severe indigestion, abdominal swelling, and frequent diarrhea. These symptoms are common for all forms of stomach cancer but when cancer spreads to the upper part of the chest, the symptoms become far more severe and may eventually cause death. Stomach cancer has the highest survival rate of any type of cancer in the world. Crocetin (trade name Eulexin) is the first Stomach Cancer Drug that is used in the treatment of gastric cancer. It was later on approved for treating peritoneal mesothelioma but was not marketed extensively due to its negative outcomes at the beginning.
Increasing prevalence of stomach cancer is expected to drive growth of the global stomach cancer drugs market during the forecast period. According to the American Cancer Society (ACS), in 2020, around 27,600 new cases of stomach cancer are expected to be diagnosed in the U.S. According to the World Cancer Research Fund, in 2018, over 1 million new cases of cancer were diagnosed across the globe. Stomach cancer is the fourth most commonly occurring cancer in men and the seventh most commonly occurring cancer in women. As a result of this, the demand for stomach cancer drugs has increased significantly worldwide for adequate treatment options. Hence, these factors are expected to drive growth of the global stomach cancer drugs market during the forecast period. Moreover, the advent of the novel therapies for metastatic stomach cancer is expected to boost the global stomach cancer drugs market growth over the forecast period.
However, high cost associated with cancer therapy combined with side-effects of cancer drugs such as appetite loss, diarrhea, anemia, and constipation is expected to hamper the global stomach cancer drugs market growth over the forecast period. Among regions, Asia Pacific is expected to witness significant growth in the global stomach cancer drugs market during the forecast period. This is owing to the presence of a large patient pool across the region. Moreover, North America is expected to register a robust growth rate over the forecast period, owing to the presence of major market players such as Eli, Lily and Company, Merck, Novartis International AG, F. Hoffmann-La Roche Ltd., and Otsuka Holdings Co. Ltd.
Major companies involved in the global stomach cancer drugs market are Bristol-Myers Squibb, GlaxoSmithKline PLC, Celltrion Inc., Pfizer Inc., Sanofi, Eli, Lily and Company, Merck, Novartis International AG, F. Hoffmann-La Roche Ltd., and Otsuka Holdings Co. Ltd.
For instance, in August 2020, Celltrion Inc. received the World Health Organization (WHO) prequalification standards for its biosimilar Herzuma indicated for stomach and breast cancer.
No comments:
Post a Comment